EW vs RMD vs STE Stock Comparison

Edwards Lifesciences, Resmed and Steris Prices as of Nov 13, 2026 Peers: Industry group
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.58B
P/E
60.7x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
5 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.16B
P/E
21.4x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
5 wins
STE STERIS plc
$264.36 +21.7% 1M +1.5% 1Y
Market cap
$25.50B
P/E
30.8x
Revenue (TTM)
$6.17B
Div. yield
0.01%
Medical Devices Healthcare
1 win

Head to Head

11 decided of 12

Edwards Lifesciences leads on 5 of the 12 questions below (Edwards Lifesciences 5, Resmed 5, Steris 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionEWRMDSTELeader
Larger companyMarket capitalisation $61.58B $34.16B $25.50B EW
Cheaper on earningsLower P/E, profitable companies only 60.7x 21.4x 30.8x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 37.6x 18.5x 22.4x RMD
Faster revenue growthRevenue growth, trailing twelve months +13.4% +9.0% +8.1% EW
More profitableNet margin, trailing twelve months 15.2% 27.8% 13.4% RMD
Better return on capitalReturn on invested capital 8.7% 22.0% 9.5% RMD
Less leveragedLower net debt / EBITDA -2.5x -0.3x 0.8x EW
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +24.5% -5.0% +1.5% EW
Better 5-year returnAnnualised price return, 5 years -1.6%/yr -1.2%/yr +2.7%/yr STE
Less volatileAnnualised volatility, 1 year 25.5% 31.1% 26.8% EW
Higher overall scoreMean of the five percentile scores vs peers 77/100 80/100 70/100 RMD

Percentile Scorecard

EWRMDSTE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisEWRMDSTE
Valuation 61 #96 of 243 75 #62 of 243 73 #67 of 243
Growth 57 #99 of 228 60 #92 of 228 51 #113 of 228
Profitability 96 #10 of 222 99 #3 of 222 90 #23 of 222
Financial Health 87 #34 of 248 76 #61 of 248 64 #90 of 248
Shareholder Returns 84 #26 of 158 89 #18 of 158 75 #41 of 158
Overall 77 80 70
  • EW ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • STE ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodEWRMDSTESPY
1 month +24.0%+1.7%+21.7% -2.0%
3 months +17.0%+6.7%+13.3% -2.8%
6 months +31.7%+18.6%+24.6% +2.0%
Year to date +25.7%-0.6%+4.3% +10.6%
1 year +24.5%-5.0%+1.5% +12.2%
3 years +62.9%+62.6%+28.5% +68.1%
3 years, per year +17.7%+17.6%+8.7% +18.9%
5 years -7.6%-6.0%+14.2% +61.4%
5 years, per year -1.6%-1.2%+2.7% +10.1%
10 years +253.3%+300.2%+307.9% +248.5%
10 years, per year +13.5%+14.9%+15.1% +13.3%

Risk

MeasureEWRMDSTESPY
Volatility, 1Y 25.5%31.1%26.8% 13.6%
Downside volatility, 1Y 24.7%33.9%25.4% 13.9%
Beta vs S&P 500, 1Y 0.580.510.39 1.00
Return / volatility, 1Y 0.96-0.160.06 0.90
Max drawdown, 5Y -54.3%-49.8%-36.5% -25.4%
From 52-week high 0.0%-13.2%-1.6% -3.2%
52-week high $107.18$275.96$268.65 $779.14
52-week low $75.87$182.82$199.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleEWRMDSTE
P/E now vs peer median 60.9xmedian 26.5x 21.5xmedian 26.5x 31.1xmedian 26.5x
P/S now vs peer median 9.2xmedian 2.7x 5.9xmedian 2.7x 4.2xmedian 2.7x
EV/EBITDA now vs peer median 35.8xmedian 18.4x 15.8xmedian 18.4x 16.2xmedian 18.4x
P/FCF now vs peer median 43.3xmedian 25.4x 20.9xmedian 25.4x 27.4xmedian 25.4x
P/B now vs peer median 5.6xmedian 2.5x 5.7xmedian 2.5x 3.5xmedian 2.5x
PEG now vs peer median -6.65median 0.98 0.99median 0.98 2.04median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsEWRMDSTE
Revenue $6.67B $5.73B $6.17B
Gross profit $5.21B $3.50B $2.75B
Operating income $1.44B $1.89B $1.17B
Net income $1.02B $1.59B $829.70M
Free cash flow $1.42B $1.61B $937.20M
R&D $1.09B $393.82M $118.40M
EPS (diluted) $1.76 $11.11 $8.47
Cash & equivalents $3.11B $1.01B $531.10M
Total debt $598.80M $409.60M $1.89B
Shares (diluted) 577.60M 143.41M 97.60M
Enterprise value $44.79B $28.60B $23.63B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricEWRMDSTE
P/E 60.9x 21.5x 31.1x
P/FCF 43.3x 20.9x 27.4x
P/Operating cash flow 35.9x 19.0x 19.9x
P/S 9.2x 5.9x 4.2x
P/B 5.6x 5.7x 3.5x
P/Tangible book 6.3x 6.1x 4.4x
EV/EBITDA 35.8x 15.8x 16.2x
EV/EBIT 40.0x 17.5x 23.1x
EV/Revenue 8.6x 5.8x 4.4x
EV/FCF 40.5x 20.6x 28.8x
EV/Operating cash flow 33.6x 18.7x 21.0x
PEG (3Y EPS CAGR) -6.65 0.99 2.04

Growth

14 metrics
MetricEWRMDSTE
Revenue growth (1Y) 13.4% 9.0% 8.1%
Revenue CAGR (3Y) 16.9% 9.4% 8.6%
Gross profit growth (1Y) 13.2% 11.0% 8.8%
Gross profit CAGR (3Y) 13.7% 13.2% 9.4%
Operating income growth (1Y) 1.1% 8.5% 20.2%
Operating income CAGR (3Y) 5.8% 18.2% -4.1%
Net income growth (1Y) -25.2% 10.8% 20.2%
Net income CAGR (3Y) -10.6% 20.7% 14.6%
EPS growth (1Y) -24.5% 13.5% 21.6%
EPS CAGR (3Y) -9.2% 21.8% 15.3%
Operating cash flow growth (1Y) 68.9% -6.0% -0.9%
Operating cash flow CAGR (3Y) 18.1% 23.7% 15.0%
Free cash flow growth (1Y) 77.1% -9.0% -2.5%
Free cash flow CAGR (3Y) 20.8% 25.5% 20.5%

Profitability

14 metrics
MetricEWRMDSTE
Gross margin 78.0% 61.1% 44.6%
EBITDA margin 24.2% 36.4% 27.0%
Operating margin 21.6% 33.0% 19.0%
Pretax margin 21.5% 35.1% 18.2%
Net margin 15.2% 27.8% 13.4%
FCF margin 21.3% 28.1% 15.2%
Operating cash flow margin 25.7% 30.9% 20.9%
Return on equity 9.4% 25.4% 11.4%
Return on assets 7.2% 18.5% 7.7%
Return on invested capital 8.7% 22.0% 9.5%
Return on capital employed 11.6% 26.1% 12.3%
Asset turnover 0.5x 0.7x 0.6x
Cash conversion (OCF / net income) 1.7x 1.1x 1.6x
Stock comp / revenue 2.6% 2.0% 1.0%

Financial Health

11 metrics
MetricEWRMDSTE
Debt / assets 4.2% 5.0% 17.7%
Debt / equity 0.1x 0.1x 0.3x
Net debt / EBITDA -2.5x -0.3x 0.8x
Debt / FCF 0.4x 0.3x 2.0x
Liabilities / assets 22.5% 27.6% 32.1%
Equity / assets 77.5% 72.4% 67.9%
Interest coverage – 81.1x 20.5x
Current ratio 4.6x 2.6x 2.1x
Quick ratio 3.5x 1.5x 1.3x
Cash ratio 2.9x 0.8x 0.4x
Altman Z-score 14.42 12.00 5.98

Shareholder Returns

7 metrics
MetricEWRMDSTE
Dividend yield – 1.1% 1.0%
Net buyback yield 0.9% 4.2% 1.3%
Shareholder yield 0.9% 5.3% 2.3%
Payout ratio (earnings) – – 30.4%
Payout ratio (FCF) – – 26.9%
Dividend growth (1Y) – – 9.5%
Dividend CAGR (3Y) – – 9.6%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusEWRMDSTE
Forward P/E 37.6xFY2026 18.5xFY2027 22.4xFY2026
EPS, next fiscal year $2.85FY2026 $12.92FY2027 $11.78FY2026
EPS growth, next FY +11.3%FY2026 +15.7%FY2027 +15.8%FY2026
EPS growth, the year after +12.6% +8.9% +11.9%
Revenue, next fiscal year $7.28BFY2026 $5.99BFY2027 $6.61BFY2026
Revenue growth, next FY +19.9%FY2026 +6.0%FY2027 +11.3%FY2026
Revenue growth, the year after -2.2% -3.8% -0.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersEWRMDSTE
Held by institutions 90.6% 68.7% 97.1%
Institutions holding 1,326 889 831
Change in shares held, QoQ +20.4% +3.2% +1.1%
Institutions buying 641 404 405
Institutions selling 456 360 302
Buyers to sellers 1.41 1.12 1.34

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

EWRMDSTE
EW 1.00 0.35 0.40
RMD 0.35 1.00 0.50
STE 0.40 0.50 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, EW, RMD and STE?

Edwards Lifesciences (EW) is the largest by market capitalisation: Edwards Lifesciences (EW) $61.58B, Resmed (RMD) $34.16B, Steris (STE) $25.50B.

Which stock is cheaper, EW, RMD and STE?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Edwards Lifesciences (EW) 60.7x, Resmed (RMD) 21.4x, Steris (STE) 30.8x). On next year's consensus earnings, Resmed (RMD) is cheapest (Edwards Lifesciences (EW) 37.6x, Resmed (RMD) 18.5x, Steris (STE) 22.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Edwards Lifesciences (EW) +13.4%, Resmed (RMD) +9.0%, Steris (STE) +8.1%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Edwards Lifesciences (EW) 15.2%, Resmed (RMD) 27.8%, Steris (STE) 13.4%). On return on invested capital, Resmed (RMD) leads (Edwards Lifesciences (EW) 8.7%, Resmed (RMD) 22.0%, Steris (STE) 9.5%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Edwards Lifesciences (EW) +24.5%, Resmed (RMD) -5.0%, Steris (STE) +1.5%. Over five years, Steris (STE) compounded fastest (Edwards Lifesciences (EW) -1.6%/yr, Resmed (RMD) -1.2%/yr, Steris (STE) +2.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Edwards Lifesciences (EW) 0.00%, Resmed (RMD) 0.00%, Steris (STE) 0.01%. Edwards Lifesciences (EW) and Resmed (RMD) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Edwards Lifesciences (EW) 25.5%, Resmed (RMD) 31.1%, Steris (STE) 26.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, EW, RMD and STE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Edwards Lifesciences (EW) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.